Repurposed drugs in perioperative treatment of oncology patients (literature review)
Medicine Today and Tomorrow · 30.06.2026 · 2 (95)
DOI: 10.35339/msz.2026.95.2.shp ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine Today and Tomorrow, online erschienen am 30.06.2026. Verfasst von P.P. Sorochan und 5 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Surgical intervention remains the main method of treatment for patients with solid tumors, but such intervention can accelerate the development of tumor recurrence and/or metastasis in cancer patients. The search for effective drugs for perioperative treatment aimed at limiting the risks of cancer spread remains a relevant task. Repurposed drugs are a promising focus of attention due to their safety, availability, and potential ability to inhibit tumor progression.
Aim
To present data on the effects of antihypertensive, anti-inflammatory, antidiabetic, hypolipidemic, and antithrombotic drugs that have been identified during their perioperative use in cancer patients and to summarize the results of studies aimed at analyzing the long-term effects of perioperative treatment with these drugs. Materials and Methods. Data for the review were searched using the PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases. Data from studies published between 2010 and 2026 were analyzed and systematized. The study was carried out within the research project "Development of a technology of anti-inflammatory perioperative therapy for radiofrequency ablation of colorectal cancer liver metastases" (2025–2027), state registration No.0124U003825. Research Ethics. Sources describing studies conducted in compliance with ethical rules were analyzed.
Results
The review presents data on the effects of β-blockers, nonsteroidal anti-inflammatory drugs, metformin, statins, and antithrombotic drugs identified during their perioperative use in cancer patients. These agents are capable of exerting a direct effect on tumor cells, as well as modulating the systemic inflammatory response, angiogenesis, immune reactivity, metabolic processes, and thrombus formation, thereby potentially influencing disease progression. Data on postoperative survival of patients who underwent perioperative treatment with these drugs are provided; despite promising results, these data remain controversial and warrant further verification.
Conclusions
To date, no standard regimens for perioperative treatment of cancer patients have been developed. Given the numerous and complex processes that occur during surgical stress, the use of approaches involving drugs from different pharmacological groups may contribute to achieving better results. Keywords: oncology, surgical treatment, perioperative period, survival.
Zitieren
APA
Sorochan, P., Hromakova, I., Prokhach, N., Olkhovskyi, D., Hrechikhin, H., & Hromakova, I. (2026). Repurposed drugs in perioperative treatment of oncology patients (literature review). Medicine Today and Tomorrow, 2(95). https://doi.org/10.35339/msz.2026.95.2.shp
Vancouver
Sorochan P, Hromakova I, Prokhach N, Olkhovskyi D, Hrechikhin H, Hromakova I. Repurposed drugs in perioperative treatment of oncology patients (literature review). Medicine Today and Tomorrow. 2026;2(95). doi:10.35339/msz.2026.95.2.shp
BibTeX
@article{Sorochan2026,
author = {Sorochan, P.P. and Hromakova, I.S. and Prokhach, N.E. and Olkhovskyi, D.V. and Hrechikhin, H.V. and Hromakova, I.A.},
title = {Repurposed drugs in perioperative treatment of oncology patients (literature review)},
journal = {Medicine Today and Tomorrow},
year = {2026},
volume = {2},
number = {95},
doi = {10.35339/msz.2026.95.2.shp}
}
EUVIMED